In the MARINA and ANCHOR trials, which anti-VEGF agent demonstrated benefit for neovascular age-related macular degeneration (AMD), and what was the primary endpoint used?

• A Bevacizumab; prevention of new vessels on FFA
• B Aflibercept; improvement of 15 or more ETDRS letters at 12 months
• C Pegaptanib; maintenance of best-corrected visual acuity at 2 years
• D Ranibizumab; prevention of moderate vision loss (loss of fewer than 15 ETDRS letters) ✓

Explanation

MARINA (minimally classic/occult choroidal neovascularization) and ANCHOR (predominantly classic CNV) trials studied ranibizumab and used prevention of moderate vision loss — defined as loss of fewer than 15 ETDRS letters — as the primary endpoint. Approximately 95% of treated patients avoided moderate vision loss, and about 35% gained 15 or more letters. These trials led to FDA approval of ranibizumab for wet AMD.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.